Targets › SLC7A1
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.
High-affinity, low capacity permease involved in the transport of the cationic amino acids (arginine, lysine and ornithine) in non-hepatic tissues. (UniProt, P30825)
Open in Phaseline: the race on SLC7A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| China Medical University Hospital | B10 L-BPA Injection Boron-10 enriched L-para-boronophenylalanine (L-BPA); a boron delivery agent for boron neu | SLC7A1 | Phase 2 | Head and Neck Cancer; Malignant Brain Tumors | Dec 2026 |
Head and Neck Cancer (1) Malignant Brain Tumors (1)
small molecule (1)
China Medical University Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.